undamentalytics Newsletter
Sign in

Albemarle Corporation (ALB) stock

Add to watchlist

Add holding +

NYSE: ALB NYSE Specialty Chemicals Next results ~November 4, 2026

B+ Fundamentals grade

Albemarle Corporation is a global speciality-chemicals producer. Its operations centre on three areas: lithium, bromine, and refining catalysts. Albemarle produces lithium compounds used as a critical input in the rechargeable batteries that power electric vehicles; bromine-based products, including brominated fire-safety materials such as flame retardants that guard people and property against fire; and hydroprocessing (HPC) catalysts, which petroleum refiners use to strip sulphur and other impurities from fuels. It also makes agrichemicals.

The company earns money by selling these chemicals to manufacturers and refiners in industries such as electronics, construction, oilfield services and automotive; some refinery catalysts carry limited performance and life-cycle guarantees. Albemarle also extracts its own raw materials, drawing lithium from brine at the Salar de Atacama in Chile and running mining and conversion sites in Western Australia.

Albemarle sells in roughly 70 countries and maintains production, research and sales facilities abroad, including three production plants in China. It has agreed to divest the controlling interest in its Refining Solutions business, expected in early 2026, while retaining a 49% stake.

Based on Albemarle Corporation's 10-K filed February 11, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$87

Valuation models combined (4)

Base case. Range ~$39–$160. Weighted average of 4 models (forward price-to-earnings vs peers, residual income, justified price-to-book, revenue-to-maturity model).

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Albemarle Corporation valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds429 adding, 512 cuttingOf 77 active managers that changed their stake, 36 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Albemarle files

Where Albemarle stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $5.91bn, up 18.3% on a year earlier, faster than 7.9% a quarter earlier. Free-cash-flow margin rose to 22.7% from -3.8% a year earlier. Operating margin widened to 4.3% from -20.8%. The diluted share count is up 4.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 4 of our 5 financial-health checks. Our valuation models combined value is $90.93 a share, against a share price of $95.98.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Albemarle Corporation's trailing-twelve-month revenue grew 18.3% year on year, with a free-cash-flow margin of 22.7%. Where it stands out: free-cash-flow margin of 22.7% ranks 1 of 42 specialty chemicals companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 18.3% (+10.4pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 18.3% over the last 12 months, against a median of 6.0% for specialty chemicals companies we cover.
  • Growth speeding up. The growth rate is 10.4 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 25.0 points on a year ago.
  • Strong cash generation. 22.7% of revenue turned into free cash flow, against a median of 4.8% for specialty chemicals companies we cover.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 4.2% in a year.
  • High earnings multiple. The shares trade at 50 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 1.4 against the S&P 500.
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 15.4% over 90 days.
  • Earnings expected to fall. The consensus expects earnings per share to fall 7% next year.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$3.75 against an average estimate of $3.24: beat by 15.7%
Revenue
$1.74bn, up 31.1% on a year earlier
Share reaction
+3.8% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
specialties net sales $1.4bn to $1.6bn (FY 2026E); specialties adjusted EBITDA $275m to $325m (FY 2026E)
Next report
November 4, 2026; average EPS estimate $2.53

Albemarle's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.5%
  • 1 week-3.1%
  • 1 month-13.4%
  • This year-35.4%
  • 1 year-6.8%
  • 5 years-63.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.9B
Operating margin
4.3%
Net margin
3.8%
EPS (TTM, diluted)
$1.83

Growth

Revenue growth
+18.3%
Change in growth rate
+10.4 pts
Share count change
+4.2%

Cash

Free cash flow (TTM)
$1.3B
FCF margin
22.7%
Stock pay % of revenue
0.6%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Dividend
  3. Announcement
  4. Leadership
  5. Leadership
  6. Results
  7. Guidance
  8. Leadership
  9. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Albemarle Corporation valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Albemarle Corporation as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$12 ~$1.4–$16 Left out: out of range vs price (0.13x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$160 ~$130–$180 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$49 ~$35–$68 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$39 ~$35–$46 Included
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: earnings are positive: price-to-earnings is the better measure
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$100 ~$83–$130 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$87 ~$39–$160 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Albemarle Corporation with Specialty Chemicals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$48.41$75.61$113.58$69.41$67.13$137.88$220.27$205.67$138.22$83.63$140.26$90.56
Market value$5.4bn$8.6bn$12.8bn$7.6bn$7.1bn$14.7bn$25.7bn$24.2bn$16.3bn$9.8bn$16.5bn$11.1bn
+ Net debt (− = net cash)$3.6bn$100m$700m$1.1bn$2.4bn$2.8bn$2.0bn$1.7bn$3.3bn$2.3bn$1.6bn$245m
Enterprise value$9.0bn$8.7bn$13.5bn$8.7bn$9.6bn$17.6bn$27.6bn$25.9bn$19.6bn$12.2bn$18.1bn$11.3bn
Multiples
Price / sales 1.9x3.2x4.2x2.3x2.0x4.7x7.7x3.3x1.7x1.8x3.2x1.9x
Price / earnings 16.1x13.3xn/m11.0x13.4x39.2xn/m9.0x10.3x——49.5x
Price / free cash flow 40.6x15.9x—————37.2x——23.8x8.3x
EV / EBITDA 14.9x10.5x17.5x7.9x10.9x23.8x26.2x9.4x28.7x—62.0x12.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

37 /100

Weak moat

How hard Albemarle's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 9 / 20

    Cash operating profit has been a median 8.1% of total assets over 10 years.

  • Pricing power 4 / 20

    Gross margin has been a median 34.1%, moving by 14.7 percentage points (standard deviation) across 10 years.

  • Durability 5 / 20

    Operating margin has been a median 18.6%; its worst year was -22.3%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 5 of 10 years, at a median -0.6% of revenue.

  • Discipline 13 / 20

    The diluted share count rose 10.2% over five years; stock-based pay has been a median 0.6% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $1.6bn and EPS of $2.53 (range $1.72 to $3.40) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $11.29 +1530% $6.1bn +18%
Next $10.54 −7% $6.2bn +2%

Next year's EPS estimate has moved −15.4% in 90 days, across 18 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −10.1% on 90 days ago. In the last 30 days, 1 analyst raised Albemarle Corporation's forecast and 2 cut it.

Consensus EPS forecast Albemarle Corporation, last 90 days
$10.00 $11.00 $12.00 $13.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $12.56 Current fiscal year, 60 days ago: $11.56 Current fiscal year, 30 days ago: $11.56 Current fiscal year, 7 days ago: $11.43 Current fiscal year, Now: $11.29 $11.29 Next fiscal year, 90 days ago: $12.47 Next fiscal year, 60 days ago: $11.30 Next fiscal year, 30 days ago: $11.30 Next fiscal year, 7 days ago: $11.27 Next fiscal year, Now: $10.54 $10.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $12.56$12.47
60 days ago $11.56$11.30
30 days ago $11.56$11.30
7 days ago $11.43$11.27
Now $11.29$10.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $3.24 $3.75 +15.7%
Mar 2026 $1.31 $2.95 +124.6%
Dec 2025 −$0.49 −$0.53 −8.6%
Sept 2025 −$0.88 −$0.19 +78.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Net sales (~$10/kg LCE lithium price scenario) FY 2026E $4.1bn to $4.3bn
    “Net sales $4.1 - $4.3 billion $5.7 - $6.0 billion $7.5 - $7.8 billion” source
  • Net sales (~$20/kg LCE lithium price scenario) FY 2026E $5.7bn to $6bn
    “Net sales $4.1 - $4.3 billion $5.7 - $6.0 billion $7.5 - $7.8 billion” source
  • Net sales (~$30/kg LCE lithium price scenario) FY 2026E $7.5bn to $7.8bn
    “Net sales $4.1 - $4.3 billion $5.7 - $6.0 billion $7.5 - $7.8 billion” source
  • Specialties net sales FY 2026E $1.4bn to $1.6bn Raised
    “Specialties net sales $1.4 - $1.6 billion” source
  • Specialties adjusted EBITDA FY 2026E $275m to $325m Non-GAAP Raised
    “Specialties adjusted EBITDA $275 - $325 million” source
  • full-year 2026 capital expenditures full-year 2026 about $500m Lowered
    “Albemarle expects its full-year 2026 capital expenditures to be approximately $500 million, down 15% compared to 2025 due to ongoing capital efficiency improvements.” source
Show 19 more items
  • Depreciation and amortization FY 2026E $660m to $680m
    “Depreciation and amortization $660 - $680 million” source
  • Adjusted effective tax rate FY 2026E -50% to 30% Non-GAAP
    “Adjusted effective tax rate (a) (50)% - 30%” source
  • Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS) FY 2026E $-20m to $20m Non-GAAP
    “Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS) ($20) - $20 million” source
  • Interest and financing expenses 2026 $120m to $140m
    “Interest and financing expense is expected to be between $120 and $140 million for 2026 following the debt reduction actions completed in the first quarter of 2026.” source
  • Weighted-average common shares outstanding (diluted) FY 2026E about 136m
    “Weighted-average common shares outstanding (diluted) (b) ~136 million” source
  • Sales volumes (kilotons lithium carbonate equivalent) · Energy Storage FY 2026E 225 to 235
    “Sales volumes are expected to be in the range of 225 to 235 kilotons lithium carbonate equivalent, as increased Wodgina volumes partially offset a delay in the Talison CGP3 ramp due to a fire that occurred on June 9.” source
  • full-year cost and productivity improvements target full-year $100m to $150m
    “Delivered $100 million in year-to-date run-rate cost and productivity improvements, tracking towards the high end of our full-year target of $100 to $150 million.” source
  • Adjusted EBITDA (~$10/kg LCE lithium price scenario) FY 2026E $0.9bn to $1bn Non-GAAP
    “Adjusted EBITDA (b) $0.9 - $1.0 billion $2.4 - $2.6 billion $4.2 - $4.4 billion” source
  • Adjusted EBITDA (~$20/kg LCE lithium price scenario) FY 2026E $2.4bn to $2.6bn Non-GAAP
    “Adjusted EBITDA (b) $0.9 - $1.0 billion $2.4 - $2.6 billion $4.2 - $4.4 billion” source
  • Adjusted EBITDA (~$30/kg LCE lithium price scenario) FY 2026E $4.2bn to $4.4bn Non-GAAP
    “Adjusted EBITDA (b) $0.9 - $1.0 billion $2.4 - $2.6 billion $4.2 - $4.4 billion” source
  • Energy Storage net sales (~$10/kg LCE lithium price scenario) FY 2026E $2.5bn to $2.6bn
    “Net sales $2.5 - $2.6 billion $4.0 - $4.2 billion $5.9 - $6.1 billion” source
  • Energy Storage net sales (~$20/kg LCE lithium price scenario) FY 2026E $4bn to $4.2bn
    “Net sales $2.5 - $2.6 billion $4.0 - $4.2 billion $5.9 - $6.1 billion” source
  • Energy Storage net sales (~$30/kg LCE lithium price scenario) FY 2026E $5.9bn to $6.1bn
    “Net sales $2.5 - $2.6 billion $4.0 - $4.2 billion $5.9 - $6.1 billion” source
  • Energy Storage adjusted EBITDA (~$10/kg LCE lithium price scenario) FY 2026E $0.7bn to $0.8bn Non-GAAP
    “Adjusted EBITDA $0.7 - $0.8 billion $2.1 - $2.3 billion $3.9 - $4.1 billion” source
  • Energy Storage adjusted EBITDA (~$20/kg LCE lithium price scenario) FY 2026E $2.1bn to $2.3bn Non-GAAP
    “Adjusted EBITDA $0.7 - $0.8 billion $2.1 - $2.3 billion $3.9 - $4.1 billion” source
  • Energy Storage adjusted EBITDA (~$30/kg LCE lithium price scenario) FY 2026E $3.9bn to $4.1bn Non-GAAP
    “Adjusted EBITDA $0.7 - $0.8 billion $2.1 - $2.3 billion $3.9 - $4.1 billion” source
  • Equity in net income of unconsolidated investments (net of tax) (~$10/kg LCE lithium price scenario) · Energy Storage FY 2026E $0.2bn to $0.3bn
    “Equity in net income of unconsolidated investments (net of tax) (b) $0.2 - $0.3 billion $0.6 - $0.7 billion $1.0 - $1.1 billion” source
  • Equity in net income of unconsolidated investments (net of tax) (~$20/kg LCE lithium price scenario) · Energy Storage FY 2026E $0.6bn to $0.7bn
    “Equity in net income of unconsolidated investments (net of tax) (b) $0.2 - $0.3 billion $0.6 - $0.7 billion $1.0 - $1.1 billion” source
  • Equity in net income of unconsolidated investments (net of tax) (~$30/kg LCE lithium price scenario) · Energy Storage FY 2026E $1bn to $1.1bn
    “Equity in net income of unconsolidated investments (net of tax) (b) $0.2 - $0.3 billion $0.6 - $0.7 billion $1.0 - $1.1 billion” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

23 analysts, Oct 2026
Buy1461%
Hold939%
Sell00%

Monthly trend

  1. Oct 2026212923
  2. Sep 2026310922
  3. Aug 2026310922
  4. Jul 2026310922

Counts of recommendations published by analysts covering Albemarle Corporation, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
−99%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.2%
of shares
Employees
7,800
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −6.8%

$97.12 on October 31, 2025 to $90.56

ThenNowEffect
Revenue (last 12 months) $5.0bn $5.9bn +18.3%
P/S multiple 2.3x 1.9x −17.9%
Share count 118m 123m −4.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −25.8%

$122.08 on November 3, 2023 to $90.56

ThenNowEffect
Revenue (last 12 months) $9.7bn $5.9bn −38.9%
Net margin 40.5% 3.8% −90.6%
P/E multiple 3.7x 49.5x +1248.3%
Share count 118m 123m −3.8%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ALB+60%−7%−33%−40%+68%−35%
Industry peers (median)+17%−26%−8%+7%−15%+6%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ALB58%42%33%42%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ALB−24%−34%−61%−50%−48%−58%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 84% from November 11, 2022 to April 8, 2025. Getting back needed a 521% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$87.45 – $214.35
From 52-week high
−57.8%
vs 50-day average
−18.2%
vs 200-day average
−39.1%
Volatility (1 year)
55%
Beta vs S&P 500
1.40

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±3.0%
After a week
7 up, 5 down
typical move ±8.1%
After a month
6 up, 6 down
typical move ±10.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +3.8% −0.4% +6.2% +9.4%
May 6, 2026 +1.8% +1.1% +3.1% −20.2%
February 11, 2026 −5.7% −1.6% −0.1% −5.9%
November 5, 2025 +3.2% −0.7% +24.7% +41.5%
July 30, 2025 −5.2% −0.5% −6.0% +18.6%
April 30, 2025 −0.2% +0.7% −5.7% −6.2%
February 12, 2025 +4.7% +0.7% +9.0% −0.1%
November 6, 2024 +0.2% +3.3% +8.4% +5.2%
July 31, 2024 +0.7% +0.2% −14.5% −0.9%
May 1, 2024 +4.1% +0.6% +8.4% +1.9%
February 14, 2024 +4.7% +1.6% +5.3% +9.2%
November 1, 2023 −1.7% +3.0% −6.1% −0.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Albemarle Corporation in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Albemarle Corporation
$4B $6B $8B $10B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $9.9B Revenue (TTM), FY23 Q4: $9.6B Revenue (TTM), FY24 Q1: $8.4B Revenue (TTM), FY24 Q2: $7.5B Revenue (TTM), FY24 Q3: $6.5B Revenue (TTM), FY24 Q4: $5.4B Revenue (TTM), FY25 Q1: $5.1B Revenue (TTM), FY25 Q2: $5B Revenue (TTM), FY25 Q3: $4.9B Revenue (TTM), FY25 Q4: $5.1B Revenue (TTM), FY26 Q1: $5.5B Revenue (TTM), FY26 Q2: $5.9B $5.9B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $9.9B
FY23 Q4 $9.6B
FY24 Q1 $8.4B
FY24 Q2 $7.5B
FY24 Q3 $6.5B
FY24 Q4 $5.4B
FY25 Q1 $5.1B
FY25 Q2 $5B
FY25 Q3 $4.9B
FY25 Q4 $5.1B
FY26 Q1 $5.5B
FY26 Q2 $5.9B
Revenue growth, TTM YoY Albemarle Corporation
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 76.7% Revenue growth, TTM YoY, FY23 Q4: 31.4% Revenue growth, TTM YoY, FY24 Q1: -4.3% Revenue growth, TTM YoY, FY24 Q2: -22.8% Revenue growth, TTM YoY, FY24 Q3: -34.2% Revenue growth, TTM YoY, FY24 Q4: -44.1% Revenue growth, TTM YoY, FY25 Q1: -39.3% Revenue growth, TTM YoY, FY25 Q2: -33.0% Revenue growth, TTM YoY, FY25 Q3: -23.9% Revenue growth, TTM YoY, FY25 Q4: -4.4% Revenue growth, TTM YoY, FY26 Q1: 7.9% Revenue growth, TTM YoY, FY26 Q2: 18.3% 18.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 76.7%
FY23 Q4 31.4%
FY24 Q1 -4.3%
FY24 Q2 -22.8%
FY24 Q3 -34.2%
FY24 Q4 -44.1%
FY25 Q1 -39.3%
FY25 Q2 -33.0%
FY25 Q3 -23.9%
FY25 Q4 -4.4%
FY26 Q1 7.9%
FY26 Q2 18.3%
Operating margin (TTM) Albemarle Corporation
-60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 19.6% Operating margin (TTM), FY23 Q4: 2.6% Operating margin (TTM), FY24 Q1: -12.3% Operating margin (TTM), FY24 Q2: -22.3% Operating margin (TTM), FY24 Q3: -40.5% Operating margin (TTM), FY24 Q4: -33.0% Operating margin (TTM), FY25 Q1: -31.0% Operating margin (TTM), FY25 Q2: -20.8% Operating margin (TTM), FY25 Q3: -2.9% Operating margin (TTM), FY25 Q4: -7.1% Operating margin (TTM), FY26 Q1: -2.8% Operating margin (TTM), FY26 Q2: 4.3% 4.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 19.6%
FY23 Q4 2.6%
FY24 Q1 -12.3%
FY24 Q2 -22.3%
FY24 Q3 -40.5%
FY24 Q4 -33.0%
FY25 Q1 -31.0%
FY25 Q2 -20.8%
FY25 Q3 -2.9%
FY25 Q4 -7.1%
FY26 Q1 -2.8%
FY26 Q2 4.3%
FCF margin (TTM) Albemarle Corporation
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 4.8% FCF margin (TTM), FY23 Q4: -8.6% FCF margin (TTM), FY24 Q1: -19.3% FCF margin (TTM), FY24 Q2: -17.1% FCF margin (TTM), FY24 Q3: -22.0% FCF margin (TTM), FY24 Q4: -18.5% FCF margin (TTM), FY25 Q1: -2.8% FCF margin (TTM), FY25 Q2: -3.8% FCF margin (TTM), FY25 Q3: 2.3% FCF margin (TTM), FY25 Q4: 13.5% FCF margin (TTM), FY26 Q1: 10.5% FCF margin (TTM), FY26 Q2: 22.7% 22.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 4.8%
FY23 Q4 -8.6%
FY24 Q1 -19.3%
FY24 Q2 -17.1%
FY24 Q3 -22.0%
FY24 Q4 -18.5%
FY25 Q1 -2.8%
FY25 Q2 -3.8%
FY25 Q3 2.3%
FY25 Q4 13.5%
FY26 Q1 10.5%
FY26 Q2 22.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 2,005 2,363 2,869 2,519 2,394 2,446 2,826 2,677 3,072 3,375 3,589 3,129 3,328 7,320 9,617 5,378 5,143 5,908
Gross profit 484 742 955 899 850 771 860 970 1,106 1,217 1,258 995 998 3,075 1,186 63 669 1,407
EBITDA 287 498 615 499 684 375 605 827 769 1,112 880 738 1,052 2,771 682 −1,188 292 894
Operating income 186 402 518 400 577 271 345 601 572 912 666 506 798 2,470 252 −1,777 −367 252
Net income 178 316 392 312 413 133 335 644 55 694 533 376 124 2,690 1,573 −1,179 −511 224
Diluted EPS $1.94 $3.43 $4.28 $3.47 $4.90 $1.69 $3.00 $5.68 $0.49 $6.34 $5.02 $3.52 $1.06 $22.84 $13.36 −$11.20 −$5.76 $1.83
Growth (year on year)
Revenue −18.7% +17.8% +21.4% −12.2% −5.0% +2.1% +15.6% −5.3% +14.7% +9.9% +6.4% −12.8% +6.4% +120.0% +31.4% −44.1% −4.4% +18.3%
EBITDA −13.8% +73.5% +23.5% −18.8% +37.1% −45.2% +61.4% +36.7% −7.1% +44.7% −20.9% −16.1% +42.6% +163.3% −75.4% −274.2% — —
Operating income −15.7% +115.8% +28.8% −22.8% +44.2% −53.0% +27.2% +74.1% −4.9% +59.5% −26.9% −24.1% +57.9% +209.4% −89.8% −805.3% — —
Net income −8.2% +77.0% +24.2% −20.5% +32.6% −67.7% +151.2% +92.2% −91.5% — −23.1% −29.5% −67.1% +>999% −41.5% −175.0% — —
Diluted EPS −7.2% +76.8% +24.8% −18.9% +41.2% −65.5% +77.5% +89.3% −91.4% — −20.8% −29.9% −69.9% +>999% −41.5% −183.8% — —
Margins
Gross margin 24.1% 31.4% 33.3% 35.7% 35.5% 31.5% 30.4% 36.2% 36.0% 36.1% 35.0% 31.8% 30.0% 42.0% 12.3% 1.2% 13.0% 23.8%
EBITDA margin 14.3% 21.1% 21.4% 19.8% 28.6% 15.3% 21.4% 30.9% 25.0% 33.0% 24.5% 23.6% 31.6% 37.9% 7.1% −22.1% 5.7% 15.1%
Operating margin 9.3% 17.0% 18.0% 15.9% 24.1% 11.1% 12.2% 22.4% 18.6% 27.0% 18.6% 16.2% 24.0% 33.7% 2.6% −33.0% −7.1% 4.3%
Net margin 8.9% 13.4% 13.7% 12.4% 17.3% 5.5% 11.8% 24.0% 1.8% 20.6% 14.9% 12.0% 3.7% 36.7% 16.4% −21.9% −9.9% 3.8%
Free-cash-flow margin 12.9% 10.8% 10.3% 8.3% 11.6% 15.6% 4.7% 20.1% −0.4% −4.6% −3.7% −1.6% −18.3% 8.9% −8.6% −18.5% 13.5% 22.7%
Cash flow
Cash from operations 359 331 487 489 433 493 361 736 304 546 719 799 344 1,912 1,327 688 1,282 1,800
Capital spending 101 75 191 281 155 111 228 197 318 700 852 850 954 1,262 2,155 1,681 590 458
Free cash flow 258 256 297 208 278 382 133 539 −14 −154 −132 −52 −609 651 −828 −993 692 1,342
Stock-based pay 0 16 27 15 10 14 15 17 19 15 20 23 20 30 37 32 40 38
Free cash flow after stock pay 257 240 270 193 267 368 118 522 −33 −169 −152 −74 −630 620 −865 −1,025 652 1,304
Balance sheet
Cash 309 530 469 478 477 2,490 214 2,270 1,137 555 613 747 439 1,499 890 1,192 1,618 1,632
Total debt 813 861 764 699 1,079 3,301 3,835 2,369 1,837 1,705 3,050 3,572 2,394 3,217 4,167 3,516 3,194 1,877
Net debt (negative = net cash) 504 331 294 222 602 812 3,621 100 700 1,150 2,437 2,825 1,955 1,718 3,277 2,324 1,576 245
Diluted shares 92m 92m 92m 90m 84m 79m 112m 113m 112m 109m 106m 107m 117m 118m 118m 118m 118m 123m
Returned to shareholders
Dividends 44 50 58 0 0 0 119 135 141 145 152 162 178 184 187 189 191 191
Buybacks 6 15 178 64 582 150 0 0 250 500 0 0 — — — — — —
Total returned 50 65 236 64 582 150 119 135 391 645 152 162 178 184 187 189 191 191

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 5 checks passed · June 30, 2026
What it owns · $15.9bn
Short-term assets $3.9bnLonger-term assets $12.0bn
What it owes, and who funded it · $12.2bn
Short-term liabilities $1.9bnShareholders' equity $10.3bn
  • Short-term assets cover short-term liabilities $3.9bn of assets due within a year against $1.9bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $1.6bn of cash against $1.9bn of debt.
  • Debt below 40% of shareholders' equity Debt is 18% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 36% to 18% over five years.
  • A year's operating cash flow covers at least 20% of debt $1.8bn of operating cash flow against $1.9bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Albemarle Corporation's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$191M
Diluted share count
+4.2%
year over year
Total shareholder yield
1.8%
dividends 1.8% + buybacks 0.0% of market value
Dividend payout ratio
85%
of net income paid out
R&D spending
0.6%
of revenue
Sales & admin spending
9.4%
of revenue
Days sales outstanding
37 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in specialty chemicals
Last 12 months unless stated ALB AXTA RPM CBT FUL ESI Median
Revenue, last 12 months $5.9bn $5.2bn $8.0bn $3.6bn $3.6bn $3.5bn $906m
Revenue growth, last 12 months 18.3% 0.1% 6.0% −4.7% 1.5% 39.6% 5.4%
Revenue growth, 3-year average −15.1% 0.3% 2.8% −3.8% −0.1% 14.4% 0.9%
Revenue growth, latest quarter 31.1% 1.8% 4.8% 6.4% 5.2% 51.7% 8.3%
Gross margin 23.8% 33.6% 41.2% 22.7% 32.3% 36.6% 28.8%
Operating margin 4.3% 12.4% — 13.6% 9.5% 11.7% 4.3%
Operating margin, 3-year average −12.9% 13.3% — 15.2% 9.9% 13.0% 5.5%
Net margin 3.8% 6.5% 8.7% 5.2% 5.6% 5.9% 0.8%
Cash from operations / revenue 30.5% 13.5% 11.6% 13.7% 8.1% 8.1% 6.9%
Free-cash-flow margin 22.7% 9.6% 8.9% 7.7% 2.8% 5.2% 4.3%
Free-cash-flow margin, 3-year average 0.6% 8.7% 8.9% 9.0% 4.5% 9.1% 5.1%
Stock pay / revenue 0.6% 0.6% 0.5% 0.5% 0.7% 2.2% 1.0%
Change in share count 4.2% −1.6% −0.6% −3.7% −0.9% 0.4% 0.1%

Median of all 42 companies we cover in specialty chemicals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

42 specialty chemicals companies
Measure Company Peer median Rank
Revenue growth Growth 18.3% 6.0% 8 of 42
Change in growth rate Growth +10.4pp +1.3pp 4 of 42
Gross margin Profitability 23.8% 31.5% 26 of 40
Operating margin Profitability 4.3% 3.8% 19 of 39
Net margin Profitability 3.8% 1.7% 19 of 42
Free-cash-flow margin Cash generation 22.7% 4.8% 1 of 42
Stock pay as % of revenue Cash generation 0.6% 1.0% 12 of 36
Long-term debt as % of assets Balance sheet 11.3% 26.8% 9 of 36
Change in share count Balance sheet 4.2% 0.0% 27 of 37
Days sales outstanding Balance sheet 37 days 59 days 6 of 30

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
China $2B 39.4% ▲ 3.3%
Other Foreign Countries $1.1B 20.9% ▲ 6.3%
United States $890M 17.3% ▼ 1.3%
South Korea $790M 15.4% ▼ 13.5%
Japan $360M 7.0% ▼ 39.0%

From Albemarle Corporation's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$15.7B
Institutions reporting
940
Shares held vs prior quarter
▲ 6.9%
Positions opened / closed
112 / 156

Top buyers and sellers, Q2 2026: 429 institutions bought and 512 sold ; the biggest buyer was FMR LLC (+2.5M shares) and the biggest seller D. E. Shaw & Co., Inc (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Capital World Investors $1.3B 9.9M 8.5% ▲ 0.7%
Blackrock, Inc. $1.3B 9.5M 8.2% ▲ 8.8%
Vanguard Capital Management LLC $1B 7.7M 6.6% ▲ 0.5%
Vanguard Portfolio Management LLC $869M 6.4M 5.5% ▲ 1.9%
State Street Corp $745M 5.5M 4.8% ▲ 5.3%
Barclays PLC $445M 3.3M 2.8% ▲ 166.8%
Geode Capital Management, LLC $422M 3.1M 2.7% ▼ 8.9%
Morgan Stanley $391M 2.9M 2.5% ▲ 28.8%
FMR LLC $363M 2.7M 2.3% ▲ 1054.8%
Primecap Management Co $358M 2.7M 2.3% ▼ 0.5%
Bank Of America Corp $343M 2.5M 2.2% ▼ 14.5%
Van Eck Associates Corp $294M 2.2M 1.9% ▲ 7.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Albemarle Corporation's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $7.4M 8 trades by 3 insiders · 0% under pre-set plans
Net ▼ $7.4M net selling
Insider Date Trade Shares Price Value
Masters J Kent Chairman & CEO May 15, 2026 Sell 700 $184.52 $129,164
Masters J Kent Chairman & CEO May 15, 2026 Sell 11,867 $183.87 $2.2M
Masters J Kent Chairman & CEO May 15, 2026 Sell 3,826 $183.12 $700,617
Masters J Kent Chairman & CEO March 10, 2026 Sell 996 $171.82 $171,133
Masters J Kent Chairman & CEO March 10, 2026 Sell 5,392 $171.18 $923,003
Masters J Kent Chairman & CEO March 10, 2026 Sell 5,395 $170.26 $918,553
Norris Eric Chief Commercial Officer February 20, 2026 Sell 5,692 $165.45 $941,741
Anderson Melissa H. Chief Bus..Transformation Off. February 13, 2026 Sell 8,454 $163.71 $1.4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 23 trades and filings

No trades in Albemarle Corporation disclosed in the last 12 months; 23 earlier trades on record.

  • Jefferson Shreve(R-IN 6):Sale (full), $15,001 - $50,000, traded May 12, 2025, filed June 22, 2025
  • Jefferson Shreve(R-IN 6):Purchase, $15,001 - $50,000, traded April 7, 2025, filed May 8, 2025
  • Jefferson Shreve(R-IN 6):Sale (full), $15,001 - $50,000, traded February 24, 2025, filed March 9, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 11, 2026
  • November 5, 2025
  • July 30, 2025
  • April 30, 2025

Recent SEC filings

Data status

When each part of this page on Albemarle Corporation was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Albemarle Corporation in brief

What does Albemarle Corporation do?
Albemarle Corporation is a US-listed company in the specialty chemicals industry. Its financial year ends in December.
What is Albemarle Corporation's stock ticker?
Albemarle Corporation trades under the ticker ALB on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Albemarle Corporation's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Albemarle Corporation reported revenue of $5.9B, 18.3% higher than a year earlier, according to its SEC filings.
What is Albemarle Corporation's free cash flow?
Albemarle Corporation's free-cash-flow margin is 22.7% of revenue over the trailing twelve months, ranking 1 of the 42 specialty chemicals companies we cover.
Who are Albemarle Corporation's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Capital World Investors, Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Albemarle Corporation's market cap?
On November 2, 2026, Albemarle Corporation's market capitalisation was about $11.1B, with a price-to-earnings ratio of 49.5 and net debt of $245M. Market figures come from third-party market data and may be delayed.
Does Albemarle Corporation pay a dividend?
Yes: Albemarle Corporation paid $191M in dividends over the trailing twelve months, a dividend yield of 1.78% and a payout ratio of 85.0%.
How much debt does Albemarle Corporation have?
Albemarle Corporation's debt-to-equity ratio is 18.3%, from its latest balance sheet (35.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are Albemarle Corporation's competitors?
In our Specialty Chemicals peer group, the companies closest to Albemarle Corporation are Axalta Coating Systems Ltd., RPM International Inc, Cabot Corp, Fuller H B Co and Element Solutions Inc. The side-by-side comparison below sets their revenue, margins and growth against Albemarle Corporation's.
Are insiders buying or selling Albemarle Corporation stock?
Over the last 12 months, Albemarle Corporation's directors and officers reported 0 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Albemarle Corporation's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Albemarle Corporation announces its own schedule.